Triple-Drug Hypertension Composition for Better BP Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hypertension treatments often result in poor blood pressure control due to poor adherence, complex guidelines, and increased side effects at high doses, with monotherapy having limited potency.
Innovation Solution
A pharmaceutical composition comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker, administered at doses between 40% to 150% of the lowest hypertension therapeutic dose, optionally with a cholesterol-lowering agent, to provide synergistic therapeutic benefits and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If monotherapy is used for hypertension treatment, then treatment simplicity is maintained, but blood pressure control efficacy is limited
Solution Approach 1:
The patent combines three different antihypertensive mechanisms (ARB, diuretic, and CCB) into a single fixed-dose combination tablet. This merging approach maintains treatment simplicity by providing a single pill regimen while achieving superior blood pressure control through synergistic pharmacological effects, directly resolving the contradiction between ease of operation and reliability.
2Reliability
If high doses of antihypertensive medications are used, then blood pressure control efficacy is improved, but side effects increase and tolerability is reduced
Solution Approach 1:
The patent employs parameter changes by using sub-therapeutic doses of three different antihypertensive agents in combination. Each component is dosed at 40-80% of its usual monotherapy dose, but the combined effect achieves superior blood pressure control with reduced side effects. This approach transforms the dosage parameters from high-dose single-agent therapy to low-dose multi-agent therapy, resolving the contradiction between efficacy and harmful factors.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation combining three different active ingredients (ARB, diuretic, and CCB) with complementary mechanisms of action. This composite approach allows each component to contribute to blood pressure control through different physiological pathways, achieving enhanced efficacy at lower individual doses and reducing the harmful effects associated with high-dose monotherapy.
3Reliability
If multiple antihypertensive agents are combined, then synergistic therapeutic benefits are achieved, but formulation complexity increases
Solution Approach 1:
The patent merges three separate medications into a single fixed-dose combination tablet, achieving synergistic therapeutic benefits while simplifying the formulation into one convenient dosage form. This approach resolves the contradiction by combining multiple agents in a unified formulation that maintains therapeutic efficacy while reducing the complexity of administration and improving patient compliance.
Data Source
AI summary
Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.